on behalf of the TOTAL Investigators

Slides:



Advertisements
Similar presentations
TOTAL Randomized trial of manual aspiration Thrombectomy + PCI vs. PCI Alone in STEMI (TOTAL) SS Jolly, JA Cairns, S Yusuf, B Meeks, J Pogue, MJ Rokoss,
Advertisements

Stone p2203/Abstract/ Conclusions
ESC Congress 2009 Clinical Trial Summary Slides
A randomized comparison of RadIal Vs. femorAL access for coronary intervention in ACS (RIVAL) SS Jolly, S Yusuf, J Cairns, K Niemela, D Xavier, P Widimsky,
A randomized comparison of RadIal Vs. femorAL access for coronary intervention in ACS (RIVAL) SS Jolly, S Yusuf, J Cairns, K Niemela, D Xavier, P Widimsky,
Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
TOTAL Culprit lesion thrombus burden after manual aspiration thrombectomy or PCI alone in STEMI The OCT Substudy of the TOTAL (ThrOmbecTomy versus PCI.
on behalf of the TOTAL Investigators
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
9803mo01, 1 Trial of Routine ANgioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction The TRANSFER-AMI trial Warren.
Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.
CURE: Prior Stroke or TIA OutcomeC + ASAASAHRP value MI/stroke/ CV death 49/274 (17.9%)52/232 (22.4)0.74 (0.50, 1.10)0.13 Non-CABG TIMI major bleeding.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
ACS and Thrombosis in the Emergency Setting
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI trial Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators.
EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
on behalf of the TOTAL Investigators
RESEARCH, REDUCE III, X-AMINE ST, COOL-MI Azfar Zaman Freeman Hospital, Newcastle.
A randomized comparison of RadIal Vs. femorAL access for coronary intervention in ACS (RIVAL) SS Jolly, S Yusuf, J Cairns, K Niemela, D Xavier, P Widimsky,
No improvement in 30-day mortality with high-dose Glucose-Insulin-Potassium (GIK) infusion CREATE-ECLA - GIK Trial Presented at: American Heart Association.
Key Clinical Trials 2015 Impact Trials That Influence Clinical Practice David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2013 Medtronic, Inc. All rights reserved. UC ML.
NSTE Acute Coronary Syndromes
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
IABP用于高危PCI有价值吗? Is IABP Valuable for High-Risk PCI?
↓ 30 d mortality ↓ Distal embolization ↑ Myocardial Blush 3 ↑TIMI 3 Post De Luca et al. EHJ 2008;29:
Treatment of Thrombotic Lesions Ramesh Daggubati, MD FACC FSCAI Director of Interventional Cardiology East Carolina University Greenville, NC USA.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Rationale for TOTAL trial: randomized trial of routine aspiration ThrOmbecTomy with PCI vs. PCI ALone in patients with STEMI undergoing primary PCI Sanjit.
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
(p for noninferiority = 0.01)
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
Impact of Radial Access on Bleeding
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
Kirk N Garratt MSc MD FSCAI
Uppsala Clinical Research Center
Is There a Role for Aspiration in STEMI?
Updates in Anticoagulation: What Did We Learn From ESC 2017?
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.
PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
Modified Rankin score 0-2
SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,
3-Year Clinical Outcomes From the RESOLUTE US Study
A Systematic Review and Meta-analysis of Randomized Trials of Manual Thrombectomy in ST elevation myocardial infarction Investigators: Ashraf Alazzoni,
RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.
Mancini JG, et al. Am J Cardiol.
What oral antiplatelet therapy would you choose?
Ischemic Postconditioning
A randomized comparison of RadIal Vs
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Primary safety endpoint
IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.
FIELD: Primary outcome
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
COMPLETE TRIAL A randomized, comparative effectiveness study of
Presentation transcript:

on behalf of the TOTAL Investigators 1 year results of the TOTAL trial: Randomized trial of manual Thrombectomy in STEMI SS Jolly, JA Cairns, S Yusuf, MJ Rokoss, P Gao, B Meeks, S Kedev, G Stankovic, R Moreno, A Gershlick, S Chowdhary, S Lavi, K Niemelä, I Bernat, WJ Cantor, AN Cheema, PG Steg, RC Welsh, T Sheth, OF Bertrand, A Avezum, R Bhindi, MK Natarajan, D Horak, RCM Leung, S Kassam, SV Rao, M El-Omar, SR Mehta, JL Velianou, S Pancholy, V Džavík on behalf of the TOTAL Investigators

Disclosures TOTAL trial was funded by: Canadian Institutes of Health Research Canadian Network and Centre for Trials Internationally (CANNeCTIN) Medtronic Inc.

Rationale for Thrombectomy Major Limitation of Primary PCI: Distal Embolization and Reduced Flow Hypothesis: Aspiration thrombectomy may reduce embolization and improve clinical outcomes

The TOTAL Trial Study Design STEMI* with Primary PCI ≤12 hours of symptom onset Sample size of 10,700 for 80% power to detect a 20% Relative Risk Reduction 1:1 Randomization between strategies Routine Upfront Manual Thrombectomy followed by PCI PCI Alone (only bailout thrombectomy) Primary Outcome: CV death, MI, cardiogenic shock and class IV heart failure ≤180 days Safety Outcome: Stroke ≤30 days Bailout Thrombectomy allowed if PCI alone strategy fails: Persistent TIMI 0 or 1 flow with large thrombus after balloon pre-dilatation Persistent large thrombus after stent deployment at target lesion

Summary of Primary Results of TOTAL trial Improvement in Surrogate Outcomes (ST resolution, Distal embolization) Thrombectomy did not reduce primary outcome at 180 days Increase in stroke at 30 days Question: Would the benefit for surrogate outcomes translate into a long term benefit at 1 year? Jolly SS, et al. N Engl J Med. 2015;372:1389-1398.

Primary Outcome at 1 year Thrombectomy (N=5033) (%) PCI alone (N=5030) (%) HR 95% CI p CV death, MI, shock or class IV heart failure 395 (7.8) 394 (7.8) 1.00 (0.87 – 1.15) 0.99 CV death 179 (3.6) 192 (3.8) 0.93 (0.76 – 1.14) 0.48 Recurrent MI 125 (2.5) 118 (2.3) 1.05 (0.82 -1.36) 0.68 Cardiogenic Shock 95 (1.9) 105 (2.1) 0.90 (0.68 – 1.19) 0.47 Class IV heart failure 106 (2.1) 96 (1.9) 1.01 (0.83 – 1.45) 0.50

Safety Outcomes at 1 year   Thrombectomy (N=5033) (%) PCI alone (N=5030) (%) HR 95% CI p Stroke at 1 year 60 (1.2) 36 (0.7) 1.66 (1.10 – 2.51) 0.015 Stroke or TIA at 1 year 73 (1.4) 44 (0.9) 1.65 (1.14 – 2.40) 0.008 Landmark Analyses Stroke 180 days to 1 year 7 (0.1) 10 (0.2) 0.70 (0.27 – 1.83) 0.46

Updated Meta-analysis N=20,352 All-Cause Mortality OR 0.90 (95% CI 0.79-1.02) P=0.10

Stroke 0.9% thrombectomy vs. 0.6% PCI alone, OR 1.43 (95% CI 1.03-1.99) P=0.03

Conclusions Routine thrombectomy compared to PCI alone did not reduce CV death, MI, shock or heart failure at 1 year Routine thrombectomy was associated with increased rate of stroke Manual Thrombectomy can no longer be recommended as a routine strategy

Available Online at the Lancet